ranibizumabAmsler’s signanti-VEGF therapy
…ntravitreal anti-vascular endothelial growth factor (anti-VEGF) ranibizumab was used, which achieved rapid resolution of hyphaema with resu…
19articles mentioning drugs
61drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Ranibizumab ×
Ranibizumab
This drug is selected. Its supporting articles are shown below.
Articles mentioning Ranibizumab
19 articles · page 2 of 2faricimabranibizumabafliberceptDSMChronic subretinal fluidchronic SRFanti-VEGF therapySRF
…ltiple anti-VEGF agents, including ranibizumab, aflibercept and faricimab, over 19 months. Despite ongoing therapy, her SRF persisted and…
98.4%
faricimabbrolucizumabranibizumabafliberceptverteporfinVIEW 1–2MARINAHAWKHARRIER
…ain—ranibizumab, aflibercept (2 mg and 8 mg), brolucizumab, and faricimab—each differing in dosing interval, mechanism, and cost. Compara…
faricimab Vabysmoaflibercept Eyleabevacizumab MVASIranibizumab RanivisioBevacizumabfaricimabafliberceptRanibizumabvenous occlusionmacular degeneration+2 more
…cizumab MVASI (25 mg/mL), ranibizumab Ranivisio (0.6 mg/mL) and faricimab Vabysmo (120 mg/mL) stored in silicone-free and oil-free polypropylene …
96.4%
faricimabafliberceptranibizumabVabysmodiabetic macular oedemaretinal diseasesretinal vein occlusionAMDDME
…r centre’s experience.Aim and Objectives To evaluate the use of faricimab and its economic impact from the hospital pharmacy perspective.…
faricimabranibizumabafliberceptbrolucizumabOzurdexdiabetic macular oedemaneovascular age-related macular degenerationnAMDtertiary hospitalDME
…tervals than with previous anti-VEGF therapies, indicating that faricimab is effective for individualised dosing in real-world settings. …
faricimabranibizumabbrolucizumabafliberceptneovascular age-related macular degeneration (nAMD)Spanish National Health System
… and biosimilar ranibizumab, aflibercept 2 mg, brolucizumab and faricimab—across three dosing regimens: fixed, Pro Re Nata and Treat-and-…